BRUSSELS, BELGIUM & SAN FRANCISCO, USA – April 20, 2026 – Global biopharmaceutical leader UCB has finalized a definitive agreement…
Read More
Everest Medicines Acquires Hasten Biopharmaceuticals for $250 Million to Bolster Asia Pacific Chronic Disease Portfolio and Commercial Reach
Everest Medicines, a leading biopharmaceutical company focused on developing and commercializing innovative medicines for chronic diseases, has announced a significant…
Read More
Gilead Acquires Antibody-Drug Conjugate Pioneer Tubulis for Up to $5 Billion, Bolstering Oncology Pipeline
Sixteen months after forging a strategic collaboration, Gilead Sciences has announced its definitive agreement to acquire German biotechnology firm Tubulis,…
Read More
Merck KGaA Acquires JSR Life Sciences’ Chromatography Business to Bolster Biopharmaceutical Purification Capabilities
Germany-based Merck KGaA, a leading science and technology company, has officially completed its previously announced acquisition of the chromatography business…
Read More
Biogen Acquires Apellis Pharmaceuticals for $5.6 Billion to Bolster Immunology and Rare Disease Portfolio
Biogen, a global biotechnology company renowned for its pioneering work in neuroscience, has announced a significant strategic acquisition of Apellis…
Read More
MSD Acquires Terns Pharmaceuticals for $6.7 Billion in Strategic Move to Bolster Oncology Pipeline Ahead of Keytruda Patent Expiry
In a significant development poised to reshape the competitive landscape of cancer therapeutics, global pharmaceutical giant MSD (known as Merck…
Read More
Novartis Acquires Promising Breast Cancer Drug SNV4818 from Synnovation Therapeutics for Up to $3 Billion
Novartis has announced a significant strategic move to bolster its oncology pipeline with the acquisition of SNV4818, an investigational oral…
Read More
